HYBRID EVENT: You can participate in person at Zurich, Switzerland. or Virtually from your home or work.

Muhammad Farhan

 

Muhammad Farhan

Ajman University,
United Arab Emirates

Abstract Title: Evaluating the Role of PCSK9 Inhibitors in Reducing Cardiovascular Events Among Statin Intolerant Pa

Biography:

Muhammad Farhan, a 5th-year medical student, has published extensively on cardiovascular and gastrointestinal topics, focusing on lipid-lowering therapies, cardiovascular outcomes, and gastrointestinal neuromodulation. His recent research includes a meta-analysis of PCSK9 inhibitors for statin-intolerant patients, studies on gastric electrical stimulation in gastroparesis, and the impact of COVID-19 vaccination on vascular health. Farhan is also advancing research in breast cancer immunotherapy and robotic spine surgery. As a mentor, he guides students through systematic reviews, fostering academic rigor and practical research experience.

Research Interest:

Abstract: Objective: This study investigates the efficacy of PCSK9 inhibitors in reducing cardiovascular risk among statin-intolerant patients, focusing on major adverse cardiovascular events (MACE) and LDL-C reduction as primary outcomes. Methods: A systematic review and meta-analysis was conducted using PRISMA guidelines, including randomized controlled trials (RCTs) and observational studies. Comprehensive searches of PubMed, Cochrane Library, and Web of Science yielded 15 studies, encompassing 69 to 18,924 participants. Data were analyzed using fixed and random effects models to evaluate the pooled effect of PCSK9 inhibitors on MACE reduction, with publication bias assessed through Egger's regression. Results: PCSK9 inhibitors led to a significant reduction in LDL-C levels (50-70%), with a pooled odds ratio (OR) for MACE of 0.88, signifying a 12% cardiovascular risk reduction. Minimal heterogeneity (I² = 0%) was noted, and publication bias was negligible (p = 0.748). PCSK9 inhibitors also displayed a favorable safety profile, with minimal muscle-related adverse effects, positioning them as effective alternatives for high-risk statin-intolerant patients. Conclusion: PCSK9 inhibitors are promising alternatives for lipid-lowering therapy in statinintolerant patients, offering substantial LDL-C reduction and MACE risk mitigation. These findings support their use in clinical practice, particularly for high-risk populations unable to tolerate statins. Further studies are encouraged to explore their long-term benefits across diverse patient groups. Keywords: PCSK9 inhibitors, statin intolerance, cardiovascular risk, LDL-C reduction, major adverse cardiovascular events (MACE)